Wockhardt shares surge over 8% on successful Zaynich treatment for drug-resistant infections

Wockhardt Ltd’s shares surged 8% to ₹1,508.60 in Monday’s session following the successful use of its breakthrough antibiotic Zaynich™ (Zidebactam/Cefepime, WCK 5222) in treating a critical US patient.

The 73-year-old cancer patient, suffering from life-threatening Gram-negative bacterial infections resistant to existing treatments, underwent a successful liver transplant after a 15-day treatment with Zaynich™. The antibiotic effectively neutralized highly resistant pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae.

This success highlights Zaynich™’s potential in tackling extreme-drug resistant infections, a growing concern worldwide. The breakthrough is part of Wockhardt’s innovative antibiotic pipeline, which has already benefitted 45 patients in the US under FDA’s compassionate-use program.

The news boosted investor confidence, driving Wockhardt’s share price up ₹58.05 from its previous close of ₹1,396.95. The stock has also delivered impressive gains, with a 21% rise in one month and 238% year-to-date growth.

Wockhardt Share Price history